Flu Hype: Postdoctoral Fellow, Johns Hopkins Scientist Disputes Claims, Data by CDC on Influenza Vaccines
November 13, 2014
(New York) According to a report by News Max Health and The British Medical Journal, a Johns Hopkins Scientist, has issued a report which strongly contradicts claims made by the Centers for Disease Control and Prevention (CDC) when it comes to influenza vaccines.
The CDC pledges “To base all public health decisions on the highest quality scientific data, openly and objectively derived.” But the scientist argues that in the case of influenza vaccinations and their marketing, this is not so.
Postdoctoral Fellow, Peter Doshi, Ph.D., claims that although flu vaccines are pushed on the public in “unprecedented numbers”, they are less effective and cause more side effects than claimed by the CDC. Furthermore, Doshi states that the studies that underlie the CDC’s policy of encouraging most people to get a yearly flu shot to begin with, are low quality studies that do not substantiate claims.
According to the report, the main assertion of the CDC that fuels the push for flu vaccines each year is that influenza comes with a risk of serious complications which can cause death, especially in senior citizens and those suffering from chronic illnesses, but this is not the case, said Doshi.
When read carefully, the CDC acknowledges that studies finding any perceived reduction in death rates may be due to the something called a “healthy-user effect” — the tendency for healthier people to be vaccinated more than less-healthy people. The only randomized trial of influenza vaccine in older people found no decrease in deaths. “This means that influenza vaccines are approved for use in older people despite any clinical trials demonstrating a reduction in serious outcomes,” says Doshi.
Disclaimer: News articles on this site may contain opinions of the author, and if opinion, may not necessarily reflect the views of the site itself or the views of the owners of NewsLI.com, Long Island Media Inc., or Long Island Exchange®. For more information on our editorial policies please view our terms of service.